Humulin R Articles
Lilly to discontinue four insulin products
18 July 2005
Japan stock market week to July 4
11 July 2005
Russia/China-invested drugs plant
4 July 2005
Generex Biotech completes C$2M funding
27 June 2005
Japan stock market week to June 20
27 June 2005
Novo's Levemir Ok'd in USA for diabetes
27 June 2005
Pfizer/S-A's Exubera shows good results
27 June 2005
ML Labs to buy Quadrant for L46.7M
27 June 2005
Generex Biotech raises $2M
27 June 2005
MannKind's Technospheres give good performace
27 June 2005
FDA approves Levemir
27 June 2005
Generex/MedGen sign Oral-lyn deal
27 June 2005
OSI's GKAs give encouraging preclinical results
20 June 2005
Add-on benefits of Actos shown in study
20 June 2005
Novartis' vildagliptin improves pancreas function
20 June 2005
Positive results for Sanofi-Aventis' Lantus
20 June 2005
Generex: new offices in UK and Lebanon
13 June 2005
Tercica moves to block Insmed growth drug in USA
6 June 2005
Berna Biotech repositions Rhein Biotech GmbH
30 May 2005
Biotech announces ad campaign for Sucanon
30 May 2005
Bentley/Univ of New Hamsphire report progress
16 May 2005
Generex to debut Oral-lyn in S America
16 May 2005
France's Ipsen sees 8.6% sales growth
16 May 2005
Sucanon shipments leave for Wal-Mart, Mexico
16 May 2005
Novo Nordisk sales up 11%, EPS rises 19%
16 May 2005
Priority review for Tercica's growth agent
9 May 2005
Eli Lilly/Amylin's diabetes drug gets FDA OK
9 May 2005
New guidelines for metabolic syndrome
25 April 2005
Palatin's PT-15 effective for obesity
25 April 2005
Insmed's SomatoKine granted priority review by US FDA
22 April 2005
UPDATE: Pfizer's $4B cost-saving plan pleases investors, despite lower 2005 EPS forecast
11 April 2005
Sucanon distribution expands in Mexico
11 April 2005
FDA accepts Insmed's NDA for SomatoKine
21 March 2005
Pfizer and Sanofi-Aventis file Exubera
14 March 2005
GH for metabolic disorders in PM women?
14 March 2005
Hidden dangers of obesity reviewed
28 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Alkermes cuts 3rd-qtr loss
14 February 2005
Novo Nordisk sees 4% profits rise for 2004
14 February 2005
Positive Ph IIb data for Generex' Oral-lyn
14 February 2005
Nobex granted two US patents for PEG-based polymers
14 February 2005
Poland boosts locally-made insulin
7 February 2005
Flamel and B-MS settle terms of Basulin deal
7 February 2005
ADA and Novo Nordisk announce grant recipients
31 January 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
New product launches in 2004
31 January 2005
Prosidion begins Ph II of antidiabetes drug
24 January 2005
Tercica provides NDA update
17 January 2005
Insmed submits SomatoKine NDA
10 January 2005
Japan stock market three weeks to January 3
10 January 2005
Pharma plant built in new record time of 14.5 months
20 December 2004
Sanofi-Aventis scoops marketing awards
20 December 2004
Bioton moves towards IPO
22 November 2004
Shreya Biotech to make recombinant human insulin from end-2005
22 November 2004
Tokyo pharma stocks - week to November 8
15 November 2004
Alkermes narrows net loss for 2nd qtr
15 November 2004
Amylin narrows 3rd-qtr 2004 loss
15 November 2004
Novo Nordisk plans $100M US insulin plant
8 November 2004
Novo Nordisk's 3rd-qtr net profit rises 11%
8 November 2004
Takeda's Actoplus Met filed in USA
8 November 2004
Novo Nordisk halts DRF 2593 development
1 November 2004
Nobex and Biocon in oral insulin deal
25 October 2004
Sanofi-Aventis' Apidra cleared in EU
11 October 2004
Biotech Holdings: Latin America update
11 October 2004
Low chromium linked to CVD in diabetics
11 October 2004
Novo expands rights to Aradigm's AERx iDMS
4 October 2004
BMS terminates insulin deal with Flamel
27 September 2004
Long-term benefits with use of Exubera
20 September 2004
Insmed's anti-tumor agent enters clinic
20 September 2004
New study examines role of insulin in predicting resistance to CVD
13 September 2004
Eli Lilly/Amylin's exenatide shows promise as type 2 diabetes therapy
13 September 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Tokyo pharma stocks - 2 weeks to August 30
6 September 2004
$1M deposit for Generex from Sejong
6 September 2004
Generex expands JV with PharmaBrand
30 August 2004
Ranbaxy to market Scigen's insulin
23 August 2004
Mexican launch of Biotech's Sucanon in September
23 August 2004
FDA clears new delivery device for Aventis' Lantus
23 August 2004
Novo Nordisk posts unexpected rise in 2nd-qtr profit
23 August 2004
Lily to advance inhaled insulin
16 August 2004
Eiffel Tech makes $3M placing to accelerate development
16 August 2004
Merck & Co licenses Pierre Fabre's F50035
9 August 2004
Positive new data for Sabinsa's ForsLean
2 August 2004
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
